Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Merck to Present at Deutsche Bank 37th Annual Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/08/2012 | 02:15pm CEST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter Kellogg, executive vice president and chief financial officer and Nancy Thornberry, senior vice president and franchise head for diabetes and endocrinology are scheduled to present at the Deutsche Bank 37th Annual Health Care Conference in Boston, Mass. on May 9 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Merck
Media:
Ron Rogers, (908) 423-6449
or
Investors:
Carol Ferguson, (908) 423-4465


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
08/22 PG&E : New Mexico Educational Retirement Board Lifted Merck Co. (MRK) Holding By..
08/21DJINVESTORS : State Lost Us $12 Million -- WSJ
08/21 ASTRAZENECA : Merck get FDA OK for ovarian cancer drug
08/20 MERCK AND : Dealing with cervical cancer vaccination
08/19 ASTRAZENECA : Three new Lynparza indications for new partners AstraZeneca and Me..
08/19 ZAYO : Boothbay Fund Management Upped Zayo Group Hldgs (ZAYO) Position; Merck Sh..
08/19 MERCK AND : FDA expands use of AZ/Mercks Lynparza in the US
08/18DJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08/18 MERCK AND : AstraZeneca and Merck & Co., Inc. - LYNPARZA Receives Additional and..
08/18 ASTRAZENECA : and Merck & Co., Inc. - LYNPARZA receives additional FDA approval ..
More news
News from SeekingAlpha
08/22 LIGAND : Situated For Growth
08/22 Diagnosing Merck (Part 1 Of 2)
08/22 Biotechs in the mix on market's rally
08/22 5 Cheapest Funds For Dividend Investors
08/21 Seeking Confirmations - U.S. Stock Market
Financials ($)
Sales 2017 40 322 M
EBIT 2017 13 713 M
Net income 2017 5 621 M
Debt 2017 4 783 M
Yield 2017 3,01%
P/E ratio 2017 31,24
P/E ratio 2018 18,56
EV / Sales 2017 4,34x
EV / Sales 2018 4,20x
Capitalization 170 241 M
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,0 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY6.03%170 241
JOHNSON & JOHNSON15.83%361 535
NOVARTIS7.89%219 476
ROCHE HOLDING LTD.3.78%218 387
PFIZER2.06%197 412
SANOFI6.97%122 091